Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 8/20 | 0.56 |
| ▸ | CA2 | P00918 | 8/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989107 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL964035 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1309451 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1206249 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL146037 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL5866373 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL220281 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL368074 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2417149 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3231613 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119162735-A | Preparation method and application of flexible fluorescent sensing film based on fluorescent probe | 西安工程大学 | 2024-12-20 | — | — | CN | claimed |
| CN-118005556-A | COX-2 targeted inhibition photosensitizer capable of activating tumor cell apoptosis and preparation method and application thereof | 大连理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-117695219-A | X-ray radiation responsive proteolytic targeting chimeric nano micelle and preparation method and application thereof | 中国药科大学 | 2024-03-15 | — | — | CN | claimed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| CN-122036705-A | PROTAC compound of targeted PI3K alpha and preparation and application thereof | 三亚深海化合物资源中心 | 2026-05-15 | — | — | CN | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4714949-A1 | NOVEL COMPOUNDS CAPABLE OF INDUCING OSTEOGENIC DIFFERENTIATION | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-03-25 | — | — | EP | disclosed |
| US-20260063641-A1 | COMPOSITIONS AND METHODS FOR LABELING AND DETECTING BINDING PARTNERS | UNIV UTAH RES FOUND (US) | 2026-03-05 | — | — | US | disclosed |
| EP-3565808-B1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-6646129-B2 | Treatment of psoriasis and skin cancer | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| EP-0984936-B1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20030119855-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1306372-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S | 2002-08-08 | — | — | US | disclosed |
| US-6346520-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
| WO-1997020821-A1 | HETEROARYL DERIVATIVES | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260063641-A1 | COMPOSITIONS AND METHODS FOR LABELING AND DETECTING BINDING PARTNERS | ATIC, JMJD7, UCHL1 | TDP1 739/4885MAOA 111/4885MAOB 261/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | TDP1 4284/4885MAOA 3683/4885MAOB 4144/4885 |
| US-20030119855-A1 | Heterocycle derivatives and drugs | OPRL1, OPRK1, OPRD1 | TDP1 3703/4885MAOA 2158/4885MAOB 1906/4885 |
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | CCNC, MKI67, CCNI | TDP1 1512/4885MAOA 629/4885MAOB 302/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | TDP1 3880/4885MAOA 1793/4885MAOB 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.